Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis’ aims to assess the effectiveness and safety of the investigational drug Volixibat. This study focuses on treating itching associated with Primary Biliary Cholangitis (PBC) and its potential impact on disease progression.
The intervention being tested is Volixibat, an oral drug administered as an Ileal Bile Acid Transporter (IBAT) inhibitor. It is designed to alleviate itching in PBC patients, with dosages of 20mg and 80mg being evaluated against a placebo.
This interventional study follows a randomized, parallel assignment model with double masking for both participants and investigators. Its primary purpose is treatment, aiming to provide a new therapeutic option for PBC-related itching.
The study began on September 22, 2021, with a primary completion date yet to be announced. The most recent update was submitted on July 30, 2025, indicating ongoing recruitment.
The outcome of this study could significantly influence Mirum Pharmaceuticals’ stock performance and investor sentiment, especially if Volixibat proves effective. This development is crucial in the competitive landscape of PBC treatments.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.